A new oral pill drug approved by the FDA for treatment of pancreatic cancer extends life on average 13.2 months compared to 6.7 months for harsh chemotherapy. The drug operates through a first-in-class “molecular glue” tricomplex mechanism that targets the active, GTP-bound “ON” state of both mutant and wild-type RAS proteins. [1, 2, 3] The FDA […]